Mass. hits Novo Nordisk with subpoena over diabetes drugs
Novo Nordisk has been slapped with a subpoena from the U.S. Attorney for the District of Massachusetts that calls for the company to fork over documents regarding potential criminal offenses related to the company’s marketing and promotion of diabetes products.
Bagsværd, Denmark-based Novo Nordisk said the subpoena asks for documents that outline the promotional material of the following diabetes products: insulin aspart (NovoLog), long-acting insulin detemir (Levemir) and liraglutide (Victoza).
The company said that it will cooperate with the U.S. Attorney during the investigation and said that it cannot predict the outcome or consequences of the matter. In addition, Novo Nordisk said it could not estimate how long the investigation would take.
Bagsværd, Denmark-based Novo Nordisk said the subpoena asks for documents that outline the promotional material of the following diabetes products: insulin aspart (NovoLog), long-acting insulin detemir (Levemir) and liraglutide (Victoza).
The company said that it will cooperate with the U.S. Attorney during the investigation and said that it cannot predict the outcome or consequences of the matter. In addition, Novo Nordisk said it could not estimate how long the investigation would take.